Related content

Clazosentan: an endothelin receptor antagonist for treatment of vasospasm after subarachnoid hemorrhage

By Macdonald R Loch  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 11, 2008-11 ,pp. : 1761-1767

Informa Healthcare

Access to resources Recommend Favorite

Multiple-Dose Pharmacokinetics of Atrasentan, an Endothelin-A Receptor Antagonist

By Dutta S.  

Clinical Drug Investigation, Vol. 21, Iss. 2, 2001-02 ,pp. : 129-136

Adis International

Access to resources Recommend Favorite

Effect of Gender on the Tolerability, Safety and Pharmacokinetics of Clazosentan Following Long-Term Infusion

By van Giersbergen Paul L.M.   Dingemanse Jasper  

Clinical Drug Investigation, Vol. 27, Iss. 11, 2007-01 ,pp. : 797-802

Adis International

Access to resources Recommend Favorite

The pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability of linaclotide

By Lee Noel   Wald Arnold  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 5, 2011-05 ,pp. : 651-659

Informa Healthcare

Access to resources Recommend Favorite

Intravenous pharmacokinetics, local tolerability, and hemolysis of an SBE7‐β‐cyclodextrin formulation of the neurokinin‐1 receptor antagonist vestipitant

By  

Clinical Pharmacology In Drug Development, Vol. 4, Iss. 2, 2015-03 ,pp. : 130-136

John Wiley & Sons Inc

Access to resources Recommend Favorite